Un-audited Financial results for the quarter ended 30th June, 2026
RESULTS
▼ Concern Flagged
HIGH RISK
📅 Filed on BSE: 06 Aug 2026, 12:47 PM IST · BSE ID: 4de4af20-e2b5-429f-bdca-cb78796e32c3
View Original BSE Filing (PDF)
💡
In Simple Terms
Suven Life Sciences reported a significant consolidated net loss for the latest quarter, driven by higher R&D expenses.
🤖 AI Summary
- Consolidated Net Loss for Q1 FY27 was Rs. (12,761.03) Lakhs, significantly widening year-over-year.
- Total consolidated income for the quarter ended June 30, 2026, stood at Rs. 1,108.94 Lakhs.
- Consolidated R&D Expenses for Q1 FY27 increased to Rs. 12,383.10 Lakhs.
- Rs. 9,331.49 Lakhs received during Q1 FY27 for 1,85,70,133 warrants, with allotment pending.
- The Board approved Un-Audited Standalone and Consolidated Financial Results on August 6, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue from operations
356.58 Lakhs
91.03%
Consolidated Net Profit / (Loss)
(12,761.03) Lakhs
-147.70%
Consolidated R & D Expenses
12,383.10 Lakhs
198.50%
Consolidated Basic EPS
(4.84)
-105.08%
Paid-up equity share capital (Q1 FY27)
2,639.93 Lakhs
21.06%
🏢 How This Affects the Company
The substantial R&D expenditure suggests continued investment in drug discovery and development, aligning with the company's single segment of Research & Development.
The increased consolidated net loss and R&D expenses indicate significant cash outflows, impacting profitability and potentially requiring careful management of the Rs. 44,813.73 Lakhs balance from the preferential issue.
The high and increasing R&D expenses without corresponding revenue growth present a financial risk, dependent on future success of the research pipeline.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, particularly the increased consolidated net loss per share to Rs. (4.84) Basic EPS from Rs. (2.36) in Q1 FY26.
🔍
Management Signal
The financial results indicate management's continued commitment to significant R&D investment, demonstrated by the Rs. 12,383.10 Lakhs in R&D expenses.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — check R&D expense trend and revenue generation.
Updates on warrant allotments — monitor conversion of pending 1,85,70,133 warrants.
Company news releases — observe progress in research and development pipeline.
HIGH RISK
Significant increase in consolidated net loss and R&D expenses indicates high operational and financial risk.
💡 Investor Takeaway
Suven Life Sciences reported a consolidated Net Loss of Rs. (12,761.03) Lakhs for the quarter ended June 30, 2026, compared to a loss of Rs. (5,151.69) Lakhs in the prior year period. Consolidated R&D Expenses increased to Rs. 12,383.10 Lakhs, contributing to the loss.
⚖️ Strengths & Concerns
✅ Positives
- Successfully received Rs. 9,331.49 Lakhs during the quarter for 1,85,70,133 warrants, bolstering cash from financing activities.
- Balance of Rs. 44,813.73 Lakhs from preferential issue proceeds remains available as of June 30, 2026.
⚠️ Concerns
- Consolidated Net Loss increased to Rs. (12,761.03) Lakhs for Q1 FY27 from Rs. (5,151.69) Lakhs in Q1 FY26.
- Consolidated R&D Expenses surged to Rs. 12,383.10 Lakhs in Q1 FY27, from Rs. 4,148.84 Lakhs in Q1 FY26.
📅 Company Track Record
Previous filings indicated Suven Life Sciences Q1 FY27 consolidated net loss surged to Rs. (12,761.03) Lakhs. The Board meeting on August 6, 2026, was announced to approve these Q1 FY27 un-audited financial results.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Suven Life Sciences' consolidated net loss for Q1 FY27?
Suven Life Sciences reported a consolidated net loss of Rs. (12,761.03) Lakhs for the quarter ended June 30, 2026.
What were Suven Life Sciences' consolidated R&D expenses for the quarter ended June 30, 2026?
Consolidated R&D Expenses for Suven Life Sciences were Rs. 12,383.10 Lakhs for the quarter ended June 30, 2026.
How much income did Suven Life Sciences generate in Q1 FY27?
Suven Life Sciences' total consolidated income for the quarter ended June 30, 2026, was Rs. 1,108.94 Lakhs.
What was the amount received from preferential issue warrants during Q1 FY27?
During Q1 FY27, Suven Life Sciences received Rs. 9,331.49 Lakhs from warrant holders in respect of 1,85,70,133 warrants.
Questions based on this BSE filing only. For information purposes.